FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083743923> ?p ?o ?g. }

• W3083743923 endingPage "471" @default.
• W3083743923 startingPage "462" @default.
• W3083743923 abstract "Actualizar las recomendaciones de la Sociedad Española de Neurología para la prevención de ictus, tanto primaria como secundaria, en pacientes con hipertensión arterial. Se han planteado diferentes preguntas para identificar cuestiones prácticas para el manejo de la presión arterial (PA) en prevención de ictus, analizando cuál debe ser el objetivo de control de la presión arterial y cuáles son los fármacos más adecuados en prevención primaria, cuándo iniciar el tratamiento antihipertensivo después de un ictus, cuáles son las cifras que debemos alcanzar y qué fármacos son los más adecuados en prevención secundaria de ictus. Se ha realizado una revisión sistemática en Pubmed analizando los principales ensayos clínicos para dar respuesta a estas preguntas y se han elaborado unas recomendaciones. En prevención primaria se recomienda iniciar tratamiento antihipertensivo con cifras de PA > 140/90 mmHg, con un objetivo de control de PA < 130/80 mmHg. En prevención secundaria de ictus se recomienda iniciar tratamiento antihipertensivo pasada la fase aguda (primeras 24 h) con un objetivo de control de PA < 130/80 mmHg, siendo preferible el empleo de ARA-II o diuréticos solos o en combinación con IECA. To update the recommendations of the Spanish Society of Neurology on primary and secondary stroke prevention in patients with arterial hypertension. We proposed several questions to identify practical issues for the management of blood pressure (BP) in stroke prevention, analysing the objectives of blood pressure control, which drugs are most appropriate in primary prevention, when antihypertensive treatment should be started after a stroke, what levels we should aim to achieve, and which drugs are most appropriate in secondary stroke prevention. We conducted a systematic review of the PubMed database and analysed the main clinical trials to address these questions and establish a series of recommendations. In primary stroke prevention, antihypertensive treatment should be started in patients with BP levels > 140/90 mmHg, with a target BP of < 130/80 mmHg. In secondary stroke prevention, we recommend starting antihypertensive treatment after the acute phase (first 24 hours), with a target BP of < 130/80 mmHg. The use of angiotensin-II receptor antagonists or diuretics alone or in combination with angiotensin-converting enzyme inhibitors is preferable." @default.
• W3083743923 created "2020-09-11" @default.
• W3083743923 creator A5002659783 @default.
• W3083743923 creator A5003688409 @default.
• W3083743923 creator A5004750045 @default.
• W3083743923 creator A5018301465 @default.
• W3083743923 creator A5018988703 @default.
• W3083743923 creator A5019880814 @default.
• W3083743923 creator A5025925718 @default.
• W3083743923 creator A5028197889 @default.
• W3083743923 creator A5031771006 @default.
• W3083743923 creator A5034654702 @default.
• W3083743923 creator A5035497245 @default.
• W3083743923 creator A5051664900 @default.
• W3083743923 creator A5059786961 @default.
• W3083743923 creator A5060792245 @default.
• W3083743923 creator A5065790633 @default.
• W3083743923 creator A5070390654 @default.
• W3083743923 creator A5072926393 @default.
• W3083743923 creator A5080156579 @default.
• W3083743923 creator A5085547862 @default.
• W3083743923 date "2021-07-01" @default.
• W3083743923 modified "2023-10-17" @default.
• W3083743923 title "Prevención de ictus en pacientes con hipertensión arterial: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología" @default.
• W3083743923 cites W1592471891 @default.
• W3083743923 cites W1921891522 @default.
• W3083743923 cites W1948351962 @default.
• W3083743923 cites W1971732155 @default.
• W3083743923 cites W1999945328 @default.
• W3083743923 cites W2013773573 @default.
• W3083743923 cites W2016967725 @default.
• W3083743923 cites W2037159781 @default.
• W3083743923 cites W2053236269 @default.
• W3083743923 cites W2054796764 @default.
• W3083743923 cites W2083146113 @default.
• W3083743923 cites W2086199925 @default.
• W3083743923 cites W2103881469 @default.
• W3083743923 cites W2117701155 @default.
• W3083743923 cites W2117827372 @default.
• W3083743923 cites W2123312526 @default.
• W3083743923 cites W2127422554 @default.
• W3083743923 cites W2131506712 @default.
• W3083743923 cites W2136145230 @default.
• W3083743923 cites W2137899413 @default.
• W3083743923 cites W2141722155 @default.
• W3083743923 cites W2144710774 @default.
• W3083743923 cites W2146798390 @default.
• W3083743923 cites W2147048340 @default.
• W3083743923 cites W2198866495 @default.
• W3083743923 cites W2214323475 @default.
• W3083743923 cites W2262333767 @default.
• W3083743923 cites W2330187990 @default.
• W3083743923 cites W2402203869 @default.
• W3083743923 cites W2773119603 @default.
• W3083743923 cites W2964879579 @default.
• W3083743923 cites W3150595609 @default.
• W3083743923 cites W4234562066 @default.
• W3083743923 cites W4249101651 @default.
• W3083743923 cites W75245760 @default.
• W3083743923 doi "https://doi.org/10.1016/j.nrl.2020.04.031" @default.
• W3083743923 hasPublicationYear "2021" @default.
• W3083743923 type Work @default.
• W3083743923 sameAs 3083743923 @default.
• W3083743923 citedByCount "4" @default.
• W3083743923 countsByYear W30837439232020 @default.
• W3083743923 countsByYear W30837439232022 @default.
• W3083743923 countsByYear W30837439232023 @default.
• W3083743923 crossrefType "journal-article" @default.
• W3083743923 hasAuthorship W3083743923A5002659783 @default.
• W3083743923 hasAuthorship W3083743923A5003688409 @default.
• W3083743923 hasAuthorship W3083743923A5004750045 @default.
• W3083743923 hasAuthorship W3083743923A5018301465 @default.
• W3083743923 hasAuthorship W3083743923A5018988703 @default.
• W3083743923 hasAuthorship W3083743923A5019880814 @default.
• W3083743923 hasAuthorship W3083743923A5025925718 @default.
• W3083743923 hasAuthorship W3083743923A5028197889 @default.
• W3083743923 hasAuthorship W3083743923A5031771006 @default.
• W3083743923 hasAuthorship W3083743923A5034654702 @default.
• W3083743923 hasAuthorship W3083743923A5035497245 @default.
• W3083743923 hasAuthorship W3083743923A5051664900 @default.
• W3083743923 hasAuthorship W3083743923A5059786961 @default.
• W3083743923 hasAuthorship W3083743923A5060792245 @default.
• W3083743923 hasAuthorship W3083743923A5065790633 @default.
• W3083743923 hasAuthorship W3083743923A5070390654 @default.
• W3083743923 hasAuthorship W3083743923A5072926393 @default.
• W3083743923 hasAuthorship W3083743923A5080156579 @default.
• W3083743923 hasAuthorship W3083743923A5085547862 @default.
• W3083743923 hasBestOaLocation W30837439231 @default.
• W3083743923 hasConcept C138885662 @default.
• W3083743923 hasConcept C15708023 @default.
• W3083743923 hasConcept C71924100 @default.
• W3083743923 hasConceptScore W3083743923C138885662 @default.
• W3083743923 hasConceptScore W3083743923C15708023 @default.
• W3083743923 hasConceptScore W3083743923C71924100 @default.
• W3083743923 hasIssue "6" @default.
• W3083743923 hasLocation W30837439231 @default.
• W3083743923 hasOpenAccess W3083743923 @default.
• W3083743923 hasPrimaryLocation W30837439231 @default.

• next